Deryk Loo
Vice President MacroGenics
Deryk Loo is a seasoned biotechnology professional currently serving as Vice President at MacroGenics, Inc. With over two decades of experience in the field, he has developed a robust expertise in antibody-drug conjugates, monoclonal antibodies, and biomarker discovery, leading to the initiation of clinical studies for multiple ADCs. Deryk’s career trajectory showcases a consistent advancement through leadership roles, emphasizing his commitment to driving innovative drug development. His academic background includes a Ph.D. in Biochemistry and Biophysics from Oregon State University, complemented by postdoctoral work at UC Irvine and Bristol Myers Squibb. Deryk is known for his strategic vision and ability to navigate complex challenges in the biotech sector. He has successfully led teams in both biotech and pharma settings, fostering collaboration between research and clinical development.
Seminars
Despite ADC’s raging success in oncology in the clinic, translational barriers still plague ADC development, with preclinical activity not matching early clinical safety and efficacy readouts and therapeutic index
As the field turns its attention to advance novel conjugate translation, join your peers to best leverage preclinical tools and understand rationale to effectively characterise safety and efficacy to minimise the ADC translational mismatch
Workshop highlights include:
- Gleaning insights from PDX models alongside emerging capabilities and challenges from in vitro and organoid models
- Understanding translational considerations for novel conjugates including bispecific ADCs and combination therapies
- Delving into in vitro pharmacology studies with high content imaging to better understand ADC trafficking, favourable design characteristics and considerations for nonspecific uptake
